Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
| Autor: | Paula M Hale, Robert E. Ratner, C.T. Chang, Alan M. Garber, Bruce W. Bode, Robert R. Henry |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Blood Glucose
Male dipeptidyl peptidase-4 medicine.medical_specialty exenatide Endocrinology Diabetes and Metabolism Population Type 2 diabetes Lower risk Gastroenterology Endocrinology Double-Blind Method Glucagon-Like Peptide 1 Internal medicine Diabetes mellitus Internal Medicine medicine Humans Hypoglycemic Agents glimepiride education Glycated Hemoglobin GLP-1 analogue education.field_of_study Liraglutide business.industry Body Weight Original Articles Middle Aged medicine.disease Glimepiride Sulfonylurea Compounds Treatment Outcome Diabetes Mellitus Type 2 Tolerability Female business Exenatide incretins medicine.drug |
| Zdroj: | Diabetes, Obesity & Metabolism |
| ISSN: | 1462-8902 |
| DOI: | 10.1111/j.1463-1326.2010.01356.x |
| Popis: | Aims: Most treatments for type 2 diabetes fail over time, necessitating combination therapy. We investigated the safety, tolerability and efficacy of liraglutide monotherapy compared with glimepiride monotherapy over 2 years. Methods: Participants were randomized to receive once-daily liraglutide 1.2 mg, liraglutide 1.8 mg or glimepiride 8 mg. Participants completing the 1-year randomized, double-blind, double-dummy period could continue open-label treatment for an additional year. Safety data were evaluated for the full population exposed to treatment, and efficacy data were evaluated for the full intention-to-treat (ITT) and 2-year completer populations. Outcome measures included change in glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight and frequency of nausea and hypoglycaemia. Results: For patients completing 2 years of therapy, HbA1c reductions were −0.6% with glimepiride versus −0.9% with liraglutide 1.2 mg (difference: −0.37, 95% CI: −0.71 to −0.02; p = 0.0376) and −1.1% with liraglutide 1.8 mg (difference: −0.55, 95% CI: −0.88 to −0.21; p = 0.0016). In the ITT population, HbA1c reductions were −0.3% with glimepiride versus −0.6% with liraglutide 1.2 mg (difference: −0.31, 95% CI: −0.54 to −0.08; p = 0.0076) and −0.9% with liraglutide 1.8 mg (difference: −0.60, 95% CI: −0.83 to −0.38; p < 0.0001). For both ITT and completer populations, liraglutide was more effective in reducing HbA1c, FPG and weight. Over 2 years, rates of minor hypoglycaemia [self-treated plasma glucose |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text